Prestige Consumer Healthcare Inc.

PBH Healthcare Drug Manufacturers Specialty & Generic

Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.

Revenue
+22.7%
EPS
−38.4%
Free cash flow
−38.2%
Total debt
+100.9%

Quarter to September 2026, against a year earlier

43.42 0.90 −2.03%
Market cap
$2.1B
P/E
13.7×
Fwd P/E
11.7×
Dividend yield
—
F-score
5/9
Altman Z
2.48
Beneish M
−2.53
Dividend safety
n/a
Sep '26 From the 10-Q filed 5 Nov Jun '26 Mar '26 Dec '25 Older periods
ROE
8.23% 9.12% 10.22% 10.31%

+8 more TTM periods

Piotroski F-Score
5 4 5 5
ROA
3.80% 4.30% 5.52% 5.47%
ROIC
9.59% 4.70% 6.82% 7.15%
Return on Tangible Assets
35.21% 37.38% 44.03% 44.19%
Average Days of Receivables
76.35 61.89 64.34 62.99
Free Cash Flow per Share
4.51 4.96 5.09 5.58
Free Cash Flow
214.22 235.36 246.45 267.19
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026